Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Third Quarter Financial Results
Date:11/12/2013

THE WOODLANDS, Texas, Nov. 12, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2013.

"We have continued to make significant progress in the advancement of our clinical pipeline, highlighted by our announcement of positive top-line results from a phase 2 study of LX4211 in patients with type 2 diabetes and moderate to severe renal impairment," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.Progress in Clinical Pipeline

  • LX4211:  LX4211 is a dual inhibitor of sodium-glucose transporters 1 and 2 (SGLT1 and SGLT2).  SGLT1 is primarily responsible for glucose absorption in the gastrointestinal tract and SGLT2 is responsible for most of the glucose reabsorption performed by the kidney.  Lexicon announced positive top-line results from a phase 2 study of LX4211 in patients with type 2 diabetes and moderate to severe renal impairment, and is proceeding with preparations for the initiation of Phase 3 clinical trials of LX4211 in type 2 diabetes.  Lexicon also continues to enroll patients in a phase 2 trial of LX4211 in type 1 diabetes.
  • Telotristat etiprate (LX1032):  Telotristat etiprate is an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels.  Lexicon announced top-line results from a pilot study of telotristat etiprate in patients with mild to moderate ulcerative colitis, and plans to maintain focus on its ongoing Phase 3 program for telotristat etiprate in carcinoid syndrome. Lexicon continues to enroll patients in a pivotal Phase 3 clinical trial of telotristat etiprate in carcinoid syndrome.
  • LX1033: LX1033 is an inhibitor of tryptophan hydroxylase that acts locally in the gastrointestinal tract to reduce serotonin production without impacting brain serotonin levels. Lexicon completed enrollment of patients in a Phase 2 clinical trial of LX1033 in diarrhea-predominant IBS, with top-line results expected to be released in November 2013.
  • Financial ResultsRevenues:  Lexicon's revenues for the three months ended September 30, 2013 decreased 36 percent to $0.2 million from $0.4 million for the corresponding period in 2012, primarily due to decreases in technology license fees.  For the nine months ended September 30, 2013, revenues decreased seven percent to $0.8 million from $0.9 million for the corresponding period in 2012.

    Research and Development Expenses:  Research and development expenses for the three months ended September 30, 2013 increased 32 percent to $25.4 million from $19.2 million for the corresponding period in 2012.  The increase was primarily attributable to increases in external clinical and preclinical research and development costs resulting from the advancement of our clinical pipeline, partially offset by decreases in facility costs.  For the nine months ended September 30, 2013, research and development expenses increased 13 percent to $69.4 million from $61.6 million for the corresponding period in 2012.

    Increase in Fair Value of Symphony Icon Purchase Liability:  In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated base and contingent payments.  Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.  The increase in fair value of the Symphony Icon purchase liability was $1.3 million and $5.8 million for the three months ended September 30, 2013 and 2012, respectively, and was $3.1 million and $10.1 million for the nine months ended September 30, 2013 and 2012, respectively. 

    General and Administrative Expenses:  General and administrative expenses for the three months ended September 30, 2013 increased seven percent to $4.7 million from $4.4 million for the corresponding period in 2012.  The increase was primarily attributable to increases in market research, consulting and personnel costs.  For the nine months ended September 30, 2013, general and administrative expenses increased four percent to $13.7 million from $13.1 million for the corresponding period in 2012.

    Consolidated Net Loss:  Net loss for the three months ended September 30, 2013 was $31.7 million, or $0.06 per share, compared to a net loss of $29.5 million, or $0.06 per share, in the corresponding period in 2012.  Net loss for the nine months ended September 30, 2013 was $86.7 million, or $0.17 per share, compared to a net loss of $85.3 million, or $0.18 per share, for the corresponding period in 2012.  For the three and nine months ended September 30, 2013, net loss included non-cash, stock-based compensation expense of $1.8 million and $5.7 million, respectively. For the three and nine months ended September 30, 2012, net loss included non-cash, stock-based compensation expense of $1.6 million and $4.9 million, respectively.

    Cash and Investments:  As of September 30, 2013, Lexicon had $151.2 million in cash and investments, as compared to $175.4 million as of June 30, 2013 and $223.2 million as of December 31, 2012. 

    Lexicon Conference CallLexicon management will hold a conference call to discuss its clinical development progress and financial results for the third quarter of 2013 at 11:00 a.m. Eastern Time on November 12, 2013. The dial-in number for the conference call is 888-645-5785 (within the US/Canada) or 970-300-1531 (international). The conference ID for all callers is 97923296. Investors can access a live webcast of the call at www.lexpharma.com. An archived version of the webcast will be available on the website through December 12, 2013.

    About LexiconLexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple drug programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

    Safe Harbor StatementThis press release contains "forward-looking statements", including statements relating to Lexicon's clinical development of LX4211, telotristat etiprate (LX1032) and LX1033, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX4211, telotristat etiprate (LX1032) and LX1033.  In addition, this press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211, telotristat etiprate (LX1032) and LX1033 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.Lexicon Pharmaceuticals, Inc 

    Selected Financial DataConsolidated Statements of Operations DataThree Months EndedSeptember 30,Nine Months EndedSeptember 30,(In thousands, except per share data)2013201220132012(unaudited)(unaudited)Revenues:Collaborative research$
    238$
    214$
    733$
    565Subscription and license fees-15879306Total revenues238372812871Operating expenses:Research and development, including stock-based compensation

    of $1,027, $923, $3,379 and $2,875, respectively25,40019,19269,41961,584Increase in fair value of Symphony Icon, Inc. purchase liability 1,3385,8443,07910,087General and administrative, including stock-based compensation

    of $723, $669, $2,349 and $2,030, respectively4,7164,39613,70913,123Total operating expenses31,45429,43286,20784,794Loss from operations(31,216)(29,060)(85,395)(83,923)Interest income3944136158Interest expense(492)(527)(1,494)(1,594)Other income, net1144121Consolidated net loss$
    (31,658)$  (29,539)$
    (86,712)$
    (85,338)Consolidated net loss per common share, basic and diluted$  (0.06)$  (0.06)$  (0.17)$  (0.18)Shares used in computing net loss attributable to Lexicon Pharmaceuticals, Inc.  per common share, basic and diluted513,419490,049512,980483,693 

     Consolidated Balance Sheet DataAs of September 30,As of December 31,(In thousands)20132012(unaudited)Cash and investments

    $
    51,210$
    223,208Property and equipment, net

    41,83842,634Goodwill

    44,54344,543Other intangible assets

    53,55753,557Total assets

    299,458371,778Deferred revenue

    14,09014,038Current and long-term debt

    22,28423,451Other long-term liabilities

    37,39132,283Accumulated deficit

    (986,544)(899,832)Total stockholders' equity

    185,710266,678 


    '/>"/>
    SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Lexicon to Provide First Quarter 2012 Financial Results
    2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
    3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
    4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
    5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
    6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
    7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
    8. Lexicon to Provide Second Quarter 2012 Financial Results
    9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
    10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
    11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/19/2017)... 2017  New research provides evidence that an old drug ... a study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... Parkinson,s disease, the oral drug levodopa has long been considered ... as the disease progresses, the effects of the medication can ...
    (Date:4/19/2017)... THOUSAND OAKS, Calif. , April 19, 2017 ... premium industrial buildings it is developing at Conejo ... California , to Atara Biotherapeutics, Inc. ... patients with severe and life-threatening diseases that have ... focus on allogeneic T-cell therapies for cancer, autoimmune ...
    (Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
    Breaking Medicine Technology:
    (Date:4/26/2017)... (PRWEB) , ... April 26, ... ... which provides an agile ecosystem and domain expertise for sponsors and CROs ... randomization and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
    (Date:4/25/2017)... ... 25, 2017 , ... Bellus Medical, a leader in medical ... new class of photodynamic cosmetics (PDC). , Allumera® is the first PDC cream ... of aging, and minimize the appearance of pores – all with minimal downtime ...
    (Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... they have signed an agreement to be the preferred physical therapy provider for ... and returning them to Derby City CrossFit as quickly and effectively as possible, ...
    (Date:4/25/2017)... ... April 25, 2017 , ... A stressful work environment ... can also decrease overall productivity and performance in the workplace. The goal of Clearview ... the last few weeks of April, Clearview Resolution Services will be shutting down the ...
    (Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
    Breaking Medicine News(10 mins):